Literature DB >> 7987403

Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man.

Q Y Yue1, T Tomson, J Säwe.   

Abstract

The inducibility of codeine metabolism by carbamazepine (CBZ) and cigarette smoking has been investigated. A single oral dose of 25 mg of codeine was given to seven epileptic patients before and after 3 weeks' regular CBZ treatment (400-600 mg per day). Codeine was also given to nine volunteers who were heavy smokers (20 cigarettes per day) and to nine non-smokers as controls. All subjects were found to be extensive metabolizers of codeine by O-demethylation. Urine was collected over 8 h following codeine intake. Codeine and the metabolites were analysed with HPLC. CBZ significantly increased the urinary excretion of the N-demethylated metabolite, norcodeine (NC) which led to a significant decrease in the metabolic ratio (MR) for N-demethylation. The O-demethylation was not significantly altered. The excretion of normorphine, an active metabolite formed through both O- and N-demethylation of codeine increased by almost three-fold after CBZ treatment. Contrary to CBZ treatment, cigarette smoking slightly but significantly induced the glucuronidation of codeine as shown by a decreased MR for glucuronidation in the smokers, while the O- and N-demethylations were not significantly changed as indicated by the similar MRs in smokers and in non-smokers. These results suggest that CBZ and cigarette smoking selectively induce different metabolizing enzymes. The polymorphic O-demethylation is relatively stable to these factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7987403     DOI: 10.1097/00008571-199408000-00003

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  8 in total

Review 1.  Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.

Authors:  S Rotzinger; M Bourin; Y Akimoto; R T Coutts; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

2.  Induction of the metabolism of etizolam by carbamazepine in humans.

Authors:  S Kondo; T Fukasawa; N Yasui-Furukori; T Aoshima; A Suzuki; Y Inoue; T Tateishi; K Otani
Journal:  Eur J Clin Pharmacol       Date:  2005-03-18       Impact factor: 2.953

Review 3.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 5.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 6.  Drug interactions with tobacco smoking. An update.

Authors:  S Zevin; N L Benowitz
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

7.  Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system.

Authors:  Michael H Court
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

8.  Does smoking increase the anesthetic requirement?

Authors:  Erdoğan Öztürk; Mustafa Said Aydoğan; Kazım Karaaslan; Zafer Doğan; Ufuk Topuz
Journal:  Turk J Med Sci       Date:  2019-10-24       Impact factor: 0.973

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.